Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend.
The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance.
In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%.
BSX 1 Year Price Comparison
Major Tailwinds Driving BSX Stock
Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP.
Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management.
Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF.
Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential.
Boston Scientific's 2025 Outlook Looks Promising
For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints.
Estimates for BSX Heading North
The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days.
BSX's Downsides
Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability.
Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment.
BSX Stock Valuation
With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present.
P/E Forward Twelve Months (F12M)
Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average.
How to Play BSX Stock?
Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds.
The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested.
Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Credit card debt is down in Canada — but household debt is up
Mark Ting, a partner with Foundation Wealth and On The Coast's personal finance columnist, says that while credit card debt going down may seem like a good thing, he's seeing borrowers tack on their debt to larger loans like mortgages. He shares tips on how to manage your debts and credit cards amid financial uncertainty.
Globe and Mail
2 hours ago
- Globe and Mail
WNP Launches All-in-One Hyaluronic Acid Skincare Set, Pioneering a "3-Step Scientific Skincare Method"
Culver City, California--(Newsfile Corp. - June 22, 2025) - Skincare brand WNP officially launched the "All-in-One Hyaluronic Acid Skincare Set" on its website, introducing its original "Three-Step Scientific Skincare Method." The set integrates five key skincare steps - cleansing, hydration, repair, brightening, and early-stage anti-aging - into a comprehensive skincare system based on four core innovations: nano-delivery, HTAC thermal water dynamics, 4D hyaluronic acid, and microencapsulation technology. This set offers a streamlined solution for everyday skincare needs. To view an enhanced version of this graphic, please visit: Four Key Innovations Nano-Liposome Delivery WNP utilizes nano-liposome technology to reduce Ceramide NP particle size to below 100 nm, enabling targeted delivery to the basal layer of the stratum corneum. Lab tests show it helps fill intercellular lipid gaps and reduce transepidermal water loss, offering industry-leading repair benefits for sensitive and barrier-damaged skin. HTAC Thermal Decomposition Water Dynamics WNP's toner features Italian patented HTAC technology, which protects red algae and recombinant collagen activity. Tests show it boosts natural hyaluronic acid production by 124% and cellular mitochondrial activity by 229%. 4D Hyaluronic Acid Multi-Layer Hydration Based on Bloomage Biotech's 4D hyaluronic acid formulation, four molecular weights of hyaluronic acid penetrate from the epidermis to the dermis. Combined with a water-in-oil lamellar emulsion structure, this provides deep, lasting hydration. Microencapsulated Time-Release Salicylic Acid Salicylic acid is microencapsulated for sustained release of active ingredients, delivering gentle exfoliation while minimizing irritation. Ideal for daily use on sensitive or combination-oily skin. Five Steps, One Streamlined Routine Gentle Cleansing: A non-soap amino acid cleanser with pH 5.5-6, refined through 45℃ natural crystallization to remove excess emulsifiers. Fine foam gently purifies without residue. Soothing & Hydration: A serum-texture toner that forms a water film on contact. Functions as both mist and toner for instant moisture. Targeted Hydration: 3% Hyaluronic Acid Capsules, a TikTok bestseller, delivers precise hydration without pilling. Brighten & Even: A matrix of niacinamide, SymWhite®377, and vitamin C derivatives to block melanin transfer and fade oxidized spots. Early Anti-Aging: Patented recombinant collagen, triple peptides, and multiple ceramides to rebuild elasticity and visibly firm skin within 28 days. Brand Vision "With this launch, WNP merges cutting-edge nano-delivery with a multi-dimensional hyaluronic hydration system to redefine what 'minimalist skincare' can mean," said WNP's Chief Product Spokesperson-Dr. Emily. "We believe skincare is shifting from ingredient stacking to true tech-enabled performance-and this launch is the clearest expression of that evolution." About WNP WNP (Wake Nature Perfection) is a science-driven skincare brand based in Asia, rooted in the philosophy of precision skincare. It integrates top-tier dermatological research with global innovations in active ingredients. As an industry innovator, WNP has introduced multiple "first-of-its-kind" technologies in both domestic and international markets, committed to delivering safe, effective, and targeted skincare solutions. For more information, please visit
Globe and Mail
2 hours ago
- Globe and Mail
Oil rises and US stock futures, Asian shares slip after US strike on Iran nuclear sites
NEW YORK (AP) — The price of oil rose and U.S. stock futures fell as global markets react to the U.S. strike against nuclear targets in Iran. The price of Brent crude oil, the international standard, rose 2.6% to $79 a barrel. U.S. crude rose 2.6% to $75.76 a barrel. On Saturday, U.S. forces attacked three Iranian nuclear and military sites, further increasing the stakes in the war between Israel and Iran. Futures for the S&P 500 and the Dow Jones Industrial Average slipped 0.4%, while Nasdaq futures fell 0.5%. Treasury yields were little changed. The modest moves indicate markets are taking the latest development in stride. That was evident in early Asian trading. Tokyo's Nikkei 225 index fell 0.6%. Other major regional markets also logged moderate declines. The conflict, which began with an Israeli attack against Iran on June 13, has sent oil prices yo-yoing, which has in turn caused see-saw moves for the U.S. stock market, because of rising and ebbing fears that the war could disrupt the global flow of crude. Iran is a major producer of oil and also sits on the narrow Strait of Hormuz, through which much of the world's crude passes. 'The situation remains highly fluid, and much hinges on whether Tehran opts for a restrained reaction or a more aggressive course of action,' Kristian Kerr, head of macro strategy at LPL Financial in Charlotte, North Carolina, said in a commentary. An Iran retaliation that included closing off the waterway would be technically difficult to pull off but traders are afraid Iran could severely disrupt transit through it, sending insurance rates spiking and making shippers nervous to move without U.S. Navy escorts Some analysts think Iran is unlikely to close down the waterway because the country uses it to transport its own crude, mostly to China, and oil is a major revenue source for the regime. 'It's a scorched earth possibility, a Sherman-burning-Atlanta move,' said Tom Kloza, chief market analyst at Turner Mason & Co. "It's not probable.' Kloza thinks oil futures will ease back down after initial fears blow over. Ed Yardeni, a long-time analyst, agreed, writing in a report that Tehran leaders would likely hold back. 'They aren't crazy,' he wrote in a note to investors Sunday. 'The price of oil should fall and stock markets around the world should climb higher.' Other experts aren't so sure. Andy Lipow, a Houston analyst covering oil markets for 45 years, said countries are not always rational actors and that he wouldn't be surprised if Tehran lashed out for political or emotional reasons. 'If the Strait of Hormuz was completely shut down, oil prices would rise to $120 to $130 a barrel,' said Lipow, predicting that that would translate to about $4.50 a gallon at the pump and hurt consumers in other ways. 'It would mean higher prices for all those goods transported by truck, and it would be more difficult for the Fed to lower interest rates.' In Asian trading early Monday, Taiwan's Taiex fell 1.5% while the Kospi in South Korea lost 1%. Both Taiwan and South Korea rely heavily on oil imported through the Strait of Hormuz.
